Arcturus Therapeutics Holdings Inc. (ARCT) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ARCT currently has 28.4M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 5.58% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 28.4M shares outstanding |
28M | 0 |
| Nov 12, 2025 |
10-Q filing | 27.2M shares outstanding |
27M | 0 |
| Aug 11, 2025 |
10-Q filing | 27.1M shares outstanding |
27M | 0 |
| May 12, 2025 |
10-Q filing | 27.1M shares outstanding |
27M | 0 |
| Mar 06, 2025 |
10-K filing | 27.0M shares outstanding |
27M | 0 |
| Nov 07, 2024 |
10-Q filing | 27.1M shares outstanding |
27M | 0 |
| Aug 05, 2024 |
10-Q filing | 27.0M shares outstanding |
27M | 0 |
| May 08, 2024 |
10-Q filing | 26.9M shares outstanding |
27M | 0 |
| Mar 14, 2024 |
10-K filing | 26.6M shares outstanding |
27M | 0 |
| Nov 14, 2023 |
10-Q filing | 26.7M shares outstanding |
27M | 0 |
| Aug 07, 2023 |
10-Q filing | 26.6M shares outstanding |
27M | 0 |
| May 09, 2023 |
10-Q filing | 26.6M shares outstanding |
27M | 0 |
| Mar 29, 2023 |
10-K filing | 26.4M shares outstanding |
26M | 0 |
| Dec 23, 2022 |
S-3 filing: The filing is for a shelf offering of up to $500,000,000 of any combination of common stock, preferred stock, debt securities, warrants, rights, and/or units. |
26M | 0 |
| Nov 09, 2022 |
10-Q filing | 26.5M shares outstanding |
26M | 0 |
| Aug 09, 2022 |
10-Q filing | 26.4M shares outstanding |
26M | 0 |
| Jun 24, 2022 |
8-K filing: Arcturus Therapeutics Holdings Inc. approved an amendment to its 2019 Omnibus Equity Incentive Plan, increasing the maximum number of shares of common stock available by 3,750,000 shares and increasing the fair market value of cash or share awards for non-employee directors. |
26M | 0 |
| May 09, 2022 |
10-Q filing | 26.4M shares outstanding |
26M | 0 |
| Mar 01, 2022 |
10-K filing | 26.4M shares outstanding |
26M | 0 |
| Nov 09, 2021 |
10-Q filing | 26.4M shares outstanding |
26M | 0 |
| Aug 10, 2021 |
10-Q filing | 26.3M shares outstanding |
26M | 0 |
| May 10, 2021 |
10-Q filing | 26.3M shares outstanding |
26M | 0 |
| Mar 01, 2021 |
10-K filing | 26.3M shares outstanding |
26M | 0 |
| Feb 22, 2021 |
8-K filing: Arcturus Therapeutics Holdings Inc. issued 74,713 shares of its common stock to Alexion Pharmaceuticals, Inc. on February 19, 2021, at a price of $66.92 per share, in exchange for an exclusive license agreement. |
26M | 0 |
| Dec 08, 2020 |
8-K filing: Arcturus Therapeutics Holdings Inc. completed a public offering of 1,365,000 shares of common stock at $110.00 per share, with net proceeds expected to be approximately $140.5 million, excluding any exercise of the Underwriters' option to purchase additional shares. ($150.15M proceeds) |
24M | 0 |
| Nov 09, 2020 |
10-Q filing | 24.5M shares outstanding |
24M | 0 |
| Aug 10, 2020 |
10-Q filing | 24.4M shares outstanding |
24M | 0 |
| Jul 29, 2020 |
8-K filing: Arcturus Therapeutics Holdings Inc. entered into an underwriting agreement for a public offering of 3,264,151 shares of common stock at $53.00 per share, with an option for the underwriters to purchase an additional 489,622 shares. ($162.0M proceeds) |
20M | 0 |
| May 22, 2020 |
S-3/A filing: The filing relates to the potential sale of up to 3,000,000 shares of common stock by a selling stockholder. |
20M | 0 |
| May 21, 2020 |
8-K filing: Ultragenyx completed the exercise of its option to purchase 600,000 shares of Arcturus Therapeutics Holdings Inc.'s common stock at $16.00 per share on May 20, 2020. ($9.6M proceeds) |
20M | 0 |
| May 08, 2020 |
S-3 filing: This is an S-3 filing for a shelf offering of common stock, preferred stock, debt securities, warrants, and units with a total proposed amount of $200,000,000. |
15M | 0 |
| May 08, 2020 |
10-Q filing | 19.9M shares outstanding |
20M | 0 |
| Apr 21, 2020 |
8-K filing: Arcturus Therapeutics Holdings Inc. completed a public offering of 4,735,297 shares of common stock, including the exercise of an over-allotment option, resulting in net proceeds of approximately $75.3 million. ($75.3M proceeds) |
15M | 0 |
| Apr 17, 2020 |
8-K filing: Arcturus Therapeutics Holdings Inc. entered into an underwriting agreement for a public offering of 4,117,650 shares of common stock at $17.00 per share, with an option for the underwriters to purchase an additional 617,647 shares. ($70.0M proceeds) |
15M | 0 |
| Mar 16, 2020 |
10-K filing | 15.1M shares outstanding |
15M | 0 |